Harnessing the Power of a DNA-Delivery Platform to Address Chronic Inflammatory Diseases

Time: 11:30 am
day: Track B - Day 1 AM


  • Advantages of DNA-Delivery, including safety, potential flexibility and manufacturing efficiency
  • Demonstration of functionality with XT-150, addressing critical areas where other delivery modalities of IL-10 therapy have been ineffective
  • Clinical program results for XT-150, a novel immunomodulatory gene therapy for osteoarthritis pain in Phase 2B development